Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 2012. The report details a specific corporate action regarding share repurchases executed on May 9, 2012, pursuant to shareholder authority granted at the Annual General Meeting on May 3, 2012.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity figures. It focuses exclusively on share capital movements.
- Shares Purchased: 1,500,000 Ordinary shares of 25 pence each.
- Price Range: Highest price paid was 1,418.5 pence per share; lowest price paid was 1,396 pence per share.
- Treasury Holdings (Settled): 522,297,927 shares (9.39% of total issued share capital).
- Treasury Holdings (Including Unsettled): 526,797,927 shares (10.45% of current total voting rights).
- Shares in Issue (Excluding Treasury): 5,042,121,990 shares.
Material Changes
The primary material change is the reduction of outstanding shares through the repurchase of 1,500,000 shares. Consequently, the percentage of shares held in Treasury increased to 10.45% of total voting rights when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, management commentary on operations, or discussion of risks and contingencies. It is a compliance announcement confirming conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares in issue (5,042,121,990) for calculating disclosure thresholds under FSA rules.
- Confirm the current percentage of voting rights held in Treasury (10.45% including unsettled shares).
- Review the specific price range paid (1,396 to 1,418.5 pence) for the repurchased block.